Pancreatic Ductal Adenocarcinoma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Alligator Bioscience, Cardiff Oncology, Novartis, and others.

December 05
20:44 2023
Pancreatic Ductal Adenocarcinoma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Alligator Bioscience, Cardiff Oncology, Novartis, and others.

DelveInsight’s, “Pancreatic Ductal Adenocarcinoma Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Pancreatic Ductal Adenocarcinoma pipeline landscape. It covers the Pancreatic Ductal Adenocarcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pancreatic Ductal Adenocarcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report

  • DelveInsight’s Pancreatic Ductal Adenocarcinoma Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Pancreatic Ductal Adenocarcinoma.
  • The leading companies working in the Pancreatic Ductal Adenocarcinoma Market include Alligator Bioscience, Cardiff Oncology, Novartis, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Cantargia AB, Nelum Corp, GC Cell Corporation, OSE Immunotherapeutics, Eucure (Beijing) Biopharma Co., Ltd, Panbela Therapeutics, Inc., Onconic Therapeutics Inc., Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharmaceutical, Genmab, Deciphera Pharmaceuticals LLC, NGM Biopharmaceuticals, Multitude Therapeutics, Seagen Inc., Tarveda Therapeutics, I-Mab Biopharma Co. Ltd., Incyte Corporation, ZielBio, Inc., DrugCendR Inc., Bayer, TriSalus Life Sciences, Jacobio Pharma, BioLineRx Ltd., Purple Biotech Ltd., Biomea Fusion, Inc., Phanes Therapeutics, Qualigen Therapeutics, and others are evaluating new drugs for pancreatic ductal adenocarcinoma to improve the treatment landscape.
  • Promising Pancreatic Ductal Adenocarcinoma Pipeline therapies include Mitazalimab, Onvansertib, NIS793, KN046,  CAN04, NLM-001, Immuncell-LC, OSE2101, YH003, SBP-101, JPI-547, ELI-002, CEND-1, siG12D-LODER, AMP945, BMS-813160, CAN04, RMC-6236, AB122, GEN1042, DCC-3116, NGM707, AMT-151, SGN-CD228A, PEN-866, TJ033721, INCB106385, ZB131, BR55, CEND-1, BAY2287411, SD-101, JAB-21822, CM24, and others.
  • December 2023: Genentech Inc. announced a study of Phase 2 clinical trials for Autogene cevumeran and Atezolizumab. The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
  • December 2023: Georgetown University announced a study of Phase 2 clinical trials for Daratumumab and KRAS Vaccine. The goal of this clinical trial is to test the safety and tolerability of anti-CD38 monoclonal antibody (mAb), daratumumab, in combination with KRAS vaccine (Targovax TG-01/Stimulon QS-21) when given with anti-PD-1 (programmed cell death protein 1) mAb (nivolumab) in patients with advanced non-small cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma (PDAC).
  • November 2023: Agenus Inc. announced a study of Phase 2 clinical trials for Botensilimab and Gemcitabine. The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer. One group of participants will only receive chemotherapy while a second group of participants will receive botensilimab and chemotherapy.

 

Request a sample and discover the recent advances in Pancreatic Ductal Adenocarcinoma Treatment Drugs @ Pancreatic Ductal Adenocarcinoma Pipeline Report

 

In the Pancreatic Ductal Adenocarcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Ductal Adenocarcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Pancreatic Ductal Adenocarcinoma Overview

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, with an average 5-year survival rate of less than 10%. Unfortunately, the majority of patients have unresectable, locally advanced, or metastatic disease at the time of diagnosis. PDAC development is associated with a poor prognosis due to its complicated and multifactorial nature.

 

Find out more about Pancreatic Ductal Adenocarcinoma Treatment Landscape @ Drugs for Pancreatic Ductal Adenocarcinoma Treatment

 

Pancreatic Ductal Adenocarcinoma Emerging Drugs Profile

  • Onvansertib: Cardiff Oncology
  • Nadunolimab: Cantargia
  • Zimberelimab: Arcus Biosciences

 

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies Pancreatic Ductal Adenocarcinoma. The Pancreatic Ductal Adenocarcinoma companies which have their Pancreatic Ductal Adenocarcinoma drug candidates in the most advanced stage, i.e phase III include XOMA.

 

DelveInsight’s Pancreatic Ductal Adenocarcinoma pipeline report covers around 80+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous

 

Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types such as

  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Learn more about the emerging Pancreatic Ductal Adenocarcinoma Pipeline Therapies @ Pancreatic Ductal Adenocarcinoma Clinical Trials Assessment

 

Scope of the Pancreatic Ductal Adenocarcinoma Pipeline Report

  • Coverage- Global
  • Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Pancreatic Ductal Adenocarcinoma Companies- Alligator Bioscience, Cardiff Oncology, Novartis, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Cantargia AB, Nelum Corp, GC Cell Corporation, OSE Immunotherapeutics, Eucure (Beijing) Biopharma Co., Ltd, Panbela Therapeutics, Inc., Onconic Therapeutics Inc., Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharmaceutical, Genmab, Deciphera Pharmaceuticals LLC, NGM Biopharmaceuticals, Multitude Therapeutics, Seagen Inc., Tarveda Therapeutics, I-Mab Biopharma Co. Ltd., Incyte Corporation, ZielBio, Inc., DrugCendR Inc., Bayer, TriSalus Life Sciences, Jacobio Pharma, BioLineRx Ltd., Purple Biotech Ltd., Biomea Fusion, Inc., Phanes Therapeutics, Qualigen Therapeutics, and others.
  • Pancreatic Ductal Adenocarcinoma Pipeline Therapies- Mitazalimab, Onvansertib, NIS793, KN046,  CAN04, NLM-001, Immuncell-LC, OSE2101, YH003, SBP-101, JPI-547, ELI-002, CEND-1, siG12D-LODER, AMP945, BMS-813160, CAN04, RMC-6236, AB122, GEN1042, DCC-3116, NGM707, AMT-151, SGN-CD228A, PEN-866, TJ033721, INCB106385, ZB131, BR55, CEND-1, BAY2287411, SD-101, JAB-21822, CM24, and others.

 

Dive deep into rich insights for new drugs for Pancreatic Ductal Adenocarcinoma treatment, Visit @ Pancreatic Ductal Adenocarcinoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Pancreatic Ductal Adenocarcinoma Executive Summary
  3. Pancreatic Ductal Adenocarcinoma: Overview
  4. Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics
  5. Pancreatic Ductal Adenocarcinoma Therapeutic Assessment
  6. Pancreatic Ductal Adenocarcinoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. NIS 793: XOMA
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. CEND 1: Cend Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. DCC-3116: Deciphera Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. RMC-6236: REVOLUTION Medicines
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Pancreatic Ductal Adenocarcinoma Key Companies
  21. Pancreatic Ductal Adenocarcinoma Key Products
  22. Pancreatic Ductal Adenocarcinoma- Unmet Needs
  23. Pancreatic Ductal Adenocarcinoma- Market Drivers and Barriers
  24. Pancreatic Ductal Adenocarcinoma- Future Perspectives and Conclusion
  25. Pancreatic Ductal Adenocarcinoma Analyst Views
  26. Pancreatic Ductal Adenocarcinoma Key Companies
  27. Appendix

 

For further information on the Pancreatic Ductal Adenocarcinoma pipeline therapeutics, reach out @ Pancreatic Ductal Adenocarcinoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-market

Categories